LEGAL TREATMENT

A timeline of the Bayer-Cipla case.

3 March 2008: The patent office grants patent to Bayer's anti-cancer drug Nexavar

31 July 2008: Bayer writes to the Drug Controller General of India (DCGI) requesting that marketing approval for Cipla generic drug Soranib not be granted as it was a spurious adaptation of its patented drug Nexavar

31 October 2008: Bayer files a writ petition before the Delhi high court to restrain DCGI from granting marketing licence to Cipla

7 November 2008: A Delhi high court single-judge bench passes an order restraining DCGI from passing a final order on the application made by Cipla

18 August 2009: A Delhi high court single-judge bench consisting of justice S. Ravindra Bhat rejects Bayer's attempt to block DCGI from allowing Cipla to market its generic version of Nexavar. Bhat also vacates the interim order that stayed the approval given by DCGI to Cipla's application for Soranib and imposes a penalty of Rs6.75 lakh on Bayer

9 February 2010: A division bench of Delhi high court rejects Bayer's appeal and upholds single-judge bench judgement of 18 August